BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 16 2023 - 7:00AM
BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”)
(NASDAQ: BRTX), a clinical stage company focused on stem cell-based
therapies, announced today that Company CEO, Lance Alstodt, has
been invited to present at the Healthcare Virtual Conference Part
II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday,
June 20th to Thursday, June 22nd at 9:00 A.M. ET
The exponential growth in knowledge and
expertise in science and medicine continues to drive opportunities
in the healthcare space. These include multiple therapeutic
categories and emerging technologies, which our presenting
companies at this year’s Maxim Healthcare Conference are focused
on, and for many, that includes key data-driven events in 2023.
Maxim Senior Analysts will host a wide range of biotechnology and
medical device companies in a series of presentations and
interactive discussions with CEOs and key management. We will also
be hosting several topical industry panels that promise to be
timely and engaging.
This conference will be live on M-Vest. To
attend, just sign up to become an M-Vest member.
Click Here to Reserve your seat About BioRestorative
Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process
utilizes proprietary technology and involves collecting a patient’s
bone marrow, isolating and culturing stem cells from the bone
marrow and cryopreserving the cells. In an outpatient
procedure, BRTX-100 is to be injected by a physician into
the patient’s damaged disc. The treatment is intended for patients
whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery. Pursuant to
authorization received from the Food and Drug Administration, we
have commenced a Phase 2 clinical trial using BRTX-100 to
treat chronic lower back pain arising from degenerative disc
disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events or results to differ materially from those projected in the
forward-looking statements as a result of various factors and
other risks, including, without limitation, those set forth in the
Company's latest Form 10-K filed with the Securities and Exchange
Commission and other public filings. You should consider these
factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Apr 2024 to May 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From May 2023 to May 2024